Hta Policies

Alec Morton of NUS explains how AI is changing health technology assessment, what stays human, and why cheaper analysis could mean more health economics.

France reimbursed 90% of drug costs in 2024, yet many patients still feel shortchanged. Maurice-Pierre Planel breaks down the numbers behind the paradox. #SyenzaNews #MarketAccess #PharmaPolicy

❓ How is Portugal’s approval of ublituximab reshaping access to multiple sclerosis therapies? The decision introduces new restrictions that could limit patient options and complicate market entry for innovative MS treatments. Explore the full implications for healthcare access and regulatory strategy. #SyenzaNews #pharmaceuticals #HealthcareInnovation #MarketAccess #healthcarepolicy

Portugal's INFARMED has blocked public funding for Datroway in breast cancer, citing insufficient added value.

How is Portugal expanding access to advanced prostate cancer therapies? The country has approved reimbursement for the niraparib-abiraterone combination, strengthening patient options in oncology and highlighting progress in pharmaceutical market access. Discover what this means for treatment innovation and healthcare policy. #SyenzaNews #oncology #MarketAccess

How can Health Technology Assessment reshape funding for social care? Our latest analysis explores strategic approaches to HTA-informed funding and the vital role of support networks in building sustainable, equitable social care systems. Read the full piece to see how these strategies are driving meaningful change. #SyenzaNews #HealthEconomics #HealthcareInnovation #costeffectiveness #innovation

🚀 How is Portugal pioneering global standards in AI health governance? By developing forward-thinking regulatory frameworks and ethical guidelines, the country is ensuring responsible AI adoption across healthcare systems while fostering innovation and trust. Discover how these efforts are shaping the future of digital health worldwide. #SyenzaNews #AIinHealthcare #digitalhealth #governance #innovation

How is NICE expanding treatment options for HFpEF patients? The UK’s National Institute for Health and Care Excellence has approved finerenone, giving clinicians a new evidence-based therapy to improve outcomes in heart failure with preserved ejection fraction. This milestone broadens the therapeutic landscape and reinforces the value of targeted drug development. Read the full analysis. #SyenzaNews #pharmaceuticals #HealthcareInnovation #innovation #MarketAccess

Could conditional adoption pathways unlock faster access to better endometriosis diagnostics? 🔍 This piece outlines pragmatic routes—conditional reimbursement, coverage-with-evidence development, and staged rollouts—that balance earlier patient access with real-world evidence generation. It also highlights stakeholder alignment, outcome metrics, and market-access considerations developers and payers need to navigate. Read the full article for actionable frameworks and a checklist to responsibly bring diagnostic innovations to market. #SyenzaNews #HealthTech #clinicaltrials #MarketAccess #healthcarepolicy

What’s standing between innovative health technologies and patients in Portugal? 🔍 Portugal’s market is slowed by fragmented procurement, complex reimbursement pathways, limited real-world evidence, and regional disparities that hinder rapid adoption of HealthTech. The article outlines the key barriers and practical solutions — from centralized HTA and adaptive pricing to early stakeholder engagement and pilot programs — to accelerate access. Read the full analysis to learn how policymakers, providers, and innovators can bridge the gap. #SyenzaNews #HealthTech #HealthcareInnovation #MarketAccess #healthcarepolicy

Could cemiplimab reshape cervical cancer care — and what does that mean for access and value? 🔬 This article unpacks the clinical benefits seen in recent studies, the pricing and reimbursement hurdles limiting patient access, and pragmatic value-based strategies (e.g., managed entry agreements, budget impact framing) for payers and policymakers. Read the full analysis to learn how stakeholders can balance innovation with affordability and improve real-world access. 💡 #SyenzaNews #oncology #HealthEconomics #MarketAccess #costeffectiveness

Ready to rethink how pharmaceutical innovation pays off for Europe? 💡📈 New drugs and smarter R&D strategies are delivering measurable health benefits while boosting economic returns across manufacturing, investment, and market access — but only with the right policy incentives and collaboration between industry and payers. Read the full article to see which policy levers and investment approaches unlock the greatest returns for patients, companies, and economies. #SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #innovation